Skip to main content
Top
Published in: BMC Medical Research Methodology 1/2020

01-12-2020 | Addiction | Research article

Disease progression of cancer patients during COVID-19 pandemic: a comprehensive analytical strategy by time-dependent modelling

Authors: Atanu Bhattacharjee, Gajendra K. Vishwakarma, Souvik Banerjee, Sharvari Shukla

Published in: BMC Medical Research Methodology | Issue 1/2020

Login to get access

Abstract

Background

As the whole world is experiencing the cascading effect of a new pandemic, almost every aspect of modern life has been disrupted. Because of health emergencies during this period, widespread fear has resulted in compromised patient safety, especially for patients with cancer. It is very challenging to treat such cancer patients because of the complexity of providing care and treatment, along with COVID-19. Hence, an effective treatment comparison strategy is needed. We need to have a handy tool to understand cancer progression in this unprecedented scenario. Linking different events of cancer progression is the need of the hour. It is a huge challenge for the development of new methodology.

Methods

This article explores the time lag effect and makes a statistical inference about the best experimental arm using Accelerated Failure Time (AFT) model and regression methods. The work is presented as the occurrence of other events as a hazard rate after the first event (relapse). The time lag effect between the events is linked and analysed.

Results

The results were presented as a comprehensive analytical strategy by joining all disease progression. An AFT model applied with the transition states, and the dependency structure between the gap times was used by the auto-regression model. The effects of arms were compared using the coefficient of auto-regression and accelerated failure time (AFT) models.

Conclusions

We provide the solutions to overcome the issue with intervals between two consecutive events in motivating head and neck cancer (HNC) data. COVID-19 is not going to leave us soon. We have to conduct several cancer clinical trials in the presence of COVID-19. A comprehensive analytical strategy to analyse cancer clinical trial data during COVID-19 pandemic is presented.
Literature
2.
go back to reference Moujaess E, Kourie HR, Ghosn M. Cancer patients and research during COVID-19 pandemic: a systematic review of current evidence. Crit Rev Oncol Hematol. 2020;150:102972.CrossRefPubMedPubMedCentral Moujaess E, Kourie HR, Ghosn M. Cancer patients and research during COVID-19 pandemic: a systematic review of current evidence. Crit Rev Oncol Hematol. 2020;150:102972.CrossRefPubMedPubMedCentral
4.
go back to reference Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef
5.
go back to reference Cox DR. Regression models and life-tables. J Roy Stat Soc. 1972;34:187–202. Cox DR. Regression models and life-tables. J Roy Stat Soc. 1972;34:187–202.
8.
go back to reference Wei LJ. The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis. Stat Med. 1992;11:1871–9.CrossRefPubMed Wei LJ. The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis. Stat Med. 1992;11:1871–9.CrossRefPubMed
9.
go back to reference Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. USA: Wiley; 2011. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. USA: Wiley; 2011.
10.
go back to reference Akaike H. A Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika. 1979;66:237–42.CrossRef Akaike H. A Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika. 1979;66:237–42.CrossRef
11.
go back to reference Akaike H, et al. Likelihood of a model and information criteria. J Econ. 1981;16(1):3–14.CrossRef Akaike H, et al. Likelihood of a model and information criteria. J Econ. 1981;16(1):3–14.CrossRef
12.
go back to reference Ando T. Bayesian model selection and statistical modelling. Florida: CRC Press; 2010. Ando T. Bayesian model selection and statistical modelling. Florida: CRC Press; 2010.
13.
go back to reference Linde A. DIC in variable selection. Statistica Neerlandica. 2005;59:45–56.CrossRef Linde A. DIC in variable selection. Statistica Neerlandica. 2005;59:45–56.CrossRef
15.
go back to reference Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika. 1993;80:557–72.CrossRef Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika. 1993;80:557–72.CrossRef
16.
go back to reference Kasza J, Wraith D, Lamb K, Wolfe R. Survival analysis of time-to-event data in respiratory health research studies. Respirology. 2014;19:483–92.CrossRefPubMed Kasza J, Wraith D, Lamb K, Wolfe R. Survival analysis of time-to-event data in respiratory health research studies. Respirology. 2014;19:483–92.CrossRefPubMed
18.
go back to reference Andersen PK, Borgan O, Gill RD, Keiding N. Statistical models based on counting processes. New York: Springer-Verlag; 2012. Andersen PK, Borgan O, Gill RD, Keiding N. Statistical models based on counting processes. New York: Springer-Verlag; 2012.
19.
go back to reference Hougaard P. Analysis of multivariate survival data. New York: Springer-Verlag; 2012. Hougaard P. Analysis of multivariate survival data. New York: Springer-Verlag; 2012.
20.
go back to reference Putter H, Spitoni C. Non-parametric estimation of transition probabilities in non-Markov multi-state models: the landmark Aalen–Johansen estimator. Stat Methods Med Res. 2018;27:2081–92.CrossRefPubMed Putter H, Spitoni C. Non-parametric estimation of transition probabilities in non-Markov multi-state models: the landmark Aalen–Johansen estimator. Stat Methods Med Res. 2018;27:2081–92.CrossRefPubMed
21.
go back to reference Andersen PK, Abildstrom SZ, Rosthøj S. Competing risks as a multi-state model. Stat Methods Med Res. 2002;11:203–15.CrossRefPubMed Andersen PK, Abildstrom SZ, Rosthøj S. Competing risks as a multi-state model. Stat Methods Med Res. 2002;11:203–15.CrossRefPubMed
22.
go back to reference Bhattacharjee A. Bayesian competing risks model: an application to breast cancer clinical trial with incomplete observations. J Stat Manage Syst. 2015;18:381–404.CrossRef Bhattacharjee A. Bayesian competing risks model: an application to breast cancer clinical trial with incomplete observations. J Stat Manage Syst. 2015;18:381–404.CrossRef
Metadata
Title
Disease progression of cancer patients during COVID-19 pandemic: a comprehensive analytical strategy by time-dependent modelling
Authors
Atanu Bhattacharjee
Gajendra K. Vishwakarma
Souvik Banerjee
Sharvari Shukla
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2020
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/s12874-020-01090-z

Other articles of this Issue 1/2020

BMC Medical Research Methodology 1/2020 Go to the issue